Aurora Science
VC Fund
Milano, Italy
AurorA Science is a biotech investment company integrating an innovative financial and industrial approach in the research and development challenges. The company is focused on independent and entrepreneurial biotech start-ups in Europe with high therapeutic potential, providing industrial and financial support.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Aurora Science invests in
Stages Aurora Science invests in
Countries Aurora Science invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $22M–$22M
- Venture - Series Unknown
- $5.8M–$14M
Investment Focus
Industry
- Biotechnology 2 (50%)
- Oncology 1 (25%)
- Wellness 1 (25%)
- Health Care 1 (25%)
- Therapeutics 1 (25%)
Stage
- Series B 1 (25%)
- Venture - Series Unknown 1 (25%)
Country
- Spain 1 (25%)
- United States 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Gabriele Campi
Co-Founder & Managing Partner
|
Co-Founder & Managing Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Peptomyc
|
Peptomyc is a company focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.Currently,cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance.Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market. | $5.8M / Venture - Series Unknown / Mar 24, 2026 | |
InteRNA Technologies
|
InteRNA Technologies secures additional equity financing to progress lead program for melanoma treatmentNijmegen/Utrecht (the Netherlands) – InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces today the closing of an equity financing round. New investorsparticipating in this round include the 'Innovation & Investment Fund Gelderland', managed by PPM Oost and several business angels. | $22.4M / Series B / Feb 09, 2021 | |
|
InteRNA Technologies
|
InteRNA Technologies secures additional equity financing to progress lead program for melanoma treatmentNijmegen/Utrecht (the Netherlands) – InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces today the closing of an equity financing round. New investorsparticipating in this round include the 'Innovation & Investment Fund Gelderland', managed by PPM Oost and several business angels. | $22.4M / Series B / Feb 09, 2021 | |
|
Peptomyc
|
Peptomyc is a company focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.Currently,cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance.Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market. | $13.9M / Venture - Series Unknown / Dec 15, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Aurora Science invest in?
Aurora Science invests primarily in Biotechnology, Oncology and Wellness startups, most often at Series B and Venture - Series Unknown stage. Most of the 4 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Aurora Science's check size?
Aurora Science typically joins rounds of $22M–$22M at Series B and $5.8M–$14M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Aurora Science participates in.
How do I contact Aurora Science?
Public channels for Aurora Science include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Aurora Science?
The team at Aurora Science includes Gabriele Campi (Co-Founder & Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
